欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (3): 352-360.doi: 10.12092/j.issn.1009-2501.2018.03.019

• 综述与讲座 • 上一篇    

新型抑酸药物钾离子竞争型酸阻滞剂研发进展

赵世峰,汪荣华   

  1. 湖州市中心医院药剂科,湖州 313000,浙江
  • 收稿日期:2017-06-21 修回日期:2017-07-30 出版日期:2018-03-26 发布日期:2018-03-28
  • 作者简介:赵世峰,男,本科,副主任药师,研究方向:临床药学。 Tel:13511232123 E-mail:thecloudknows@yeah.net
  • 基金资助:

    浙江省自然科学基金青年基金项目(LQ15H280001)

Research and development progress of the novel acid suppression drugs potassium-competitive acid blockers

ZHAO Shifeng, WANG Ronghua   

  1. Department of Pharmacy, Huzhou Central Hospital, Huzhou 313000, Zhejiang, China
  • Received:2017-06-21 Revised:2017-07-30 Online:2018-03-26 Published:2018-03-28

摘要:

质子泵抑制剂(proton pump inhibitors,PPIs)的问世是酸相关性疾病治疗史上一个重要的里程碑。然而,此类药物存在着一些药动学与药效学上的缺陷。钾离子竞争型酸阻滞剂(potassium-competitive acid blockers,P-CABs)以钾离子竞争性的方式、可逆性地结合于质子泵从而达到抑制胃酸分泌的作用并且具有多种优势。本文回顾了该类药物的研发经历、药理学特点及临床研究,并着重介绍了已上市的瑞伐拉赞和沃诺拉赞,以期为酸相关性疾病的药物治疗提供新的参考。

关键词: 钾离子竞争型酸阻滞剂, 质子泵抑制剂, 酸相关性疾病, 瑞伐拉赞, 沃诺拉赞

Abstract:

The advent of proton pump inhibitors represents an important milestone in the treatment of acid related diseases. However, these drugs have some deficiencies in pharmacokinetics and pharmacodynamics. Potassium-competitive acid blockers reversibly bind to proton pumps in a competitive manner with potassium ions, thereby inhibiting gastric acid secretion and having multiple advantages. In order to provide a new reference for the treatment of acid related diseases, the research and development experience and pharmacological characteristics and clinical research of these drugs are reviewed, and the focuses are on the already listed revaprazan and vonoprazan.

Key words: potassium-competitive acid blockers, proton pump inhibitors, acid-related diseases, revaprazan, vonoprazan

中图分类号: